Development of Antiviral Therapy of HIV-1 Infection

$778,317ZIAFY2022CANIH

Division Of Clinical Sciences - Nci

Investigators

Linked publications & trials

Paper 38973505 Paper 38771724 Paper 38272319 Paper 37436982 Paper 37224601 Paper 37150084 Paper 36738797 Paper 35170223 Paper 34978889 Paper 33815322 Paper 32348139 Paper 29763303 Paper 29511083 Paper 29463535 Paper 29437300 Paper 29374261 Paper 29110408 Paper 29039736 Paper 28958624 Paper 28947797 Paper 28893602 Paper 28434781 Paper 28418652 Paper 28392419 Paper 27389367 Paper 26581995 Paper 26462551 Paper 26306007 Paper 26107245 Paper 26096678 Paper 25691652 Paper 25583709 Paper 25336073 Paper 25050776 Paper 24970894 Paper 24752271 Paper 24632447 Paper 24384694 Paper 24162098 Paper 24100493 Paper 24080647 Paper 23951362 Paper 23947685 Paper 23877703 Paper 23841536 Paper 23800377 Paper 23796932 Paper 23615903 Paper 23545667 Paper 23403426 Paper 23273211 Paper 22713337 Paper 22513406 Paper 22364812 Paper 22290878 Paper 22155823 Paper 21813613 Paper 21800876 Paper 21658961 Paper 21366961 Paper 21282450 Paper 21256008 Paper 21212528 Paper 21194227 Paper 21109922 Paper 20954335 Paper 20827746 Paper 20439612 Paper 20034787 Paper 19928916 Paper 18378711 Paper 17418430 Paper 17053352 Paper 16943297 Paper 16912524 Paper 16821774 Paper 16715409 Paper 16687179 Paper 16670635 Paper 16628725 Paper 16476734 Paper 16424013 Paper 16413396 Paper 16396777 Paper 16298819 Paper 16195329 Paper 16138346 Paper 16137563 Paper 16020669 Paper 15911439 Paper 15902284 Paper 15755508 Paper 15681411 Paper 15615545 Paper 15479842 Paper 15457679 Paper 15456247 Paper 15351348 Paper 15351209 Paper 15342380

Abstract

This year we published the "Design, Synthesis and X-Ray Structural Studies of Potent HIV-1 Protease Inhibitors Containing C-4 Substituted Tricyclic Hexahydro-Furofuran Derivatives as P2 Ligands" (ChemMedChem, May 2022). We also demonstrated "Fluorine Modifications Contribute to Potent Antiviral Activity against Highly Drug-Resistant HIV-1 and Favorable Blood-Brain Barrier Penetration Property of Novel Central Nervous System-Targeting HIV-1 Protease Inhibitors In Vitro". These results strongly suggest that GRL-08513 and GRL-08613 have favorable features for patients infected with wild-type/multidrug-resistant HIV-1 strains and might serve as candidates for a preventive and/or therapeutic agent for HAND and other CNS complications.

View original record on NIH RePORTER →